Summit Headlands LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$1,377,916	151
2024	Research	$1,953,438	37
2023	Research	$625,335	61
2022	Research	$1,127,393	68
2021	Research	$1,229,898	22

Breakdown

Who paid Research payments · program years 2021–2025

Eli Lilly and Company $2,328,822 29 payments
Moderna TX, Inc. $2,180,812 55 payments
Pfizer Inc. $922,387 44 payments
AbbVie, Inc. $585,505 171 payments
Allergan Inc. $200,598 16 payments
Biohaven Pharmaceutical Holding Company Ltd. $69,053 21 payments
AstraZeneca Pharmaceuticals LP $25,303 2 payments
Vanda Pharmaceuticals Inc. $1,500 1 payment

Studies the money was for Research payments · program years 2021–2025

A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $1,285,050 8 payments
A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $874,633 35 payments
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $728,420 29 payments
A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight and Type 2 Diabetes (Attain-2) $584,122 4 payments
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-4) $523,313 2 payments
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $357,397 4 payments
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After An Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (Surmount-3) $325,735 3 payments
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine $321,542 62 payments
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Tirzepatide Doses in Participants With Type 2 Diabetes and Obesity $201,023 4 payments
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $191,533 77 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.